 |
|
 UPCOMING EVENTS |
|
|
| |
 |
No upcoming events. |
|
|
| PAST EVENTS |
|
|
| |
|
BIO International Convention
San Diego Convention Center,
San Diego, CA; June 17-20, 2008 |
|
| |
|
Canaccord Adams Diabetes &
Obesity Conference
Hotel Nikko, San Francisco, CA; June 6, 2008 |
|
| |
|
Bank of America 37th Annual Investment Conference
The Ritz-Carlton, San Francisco, CA; September 17-19, 2007 |
|
| |
|
The 6th Annual JMP Securities Research Conference
The Ritz-Carlton, San Francisco, CA; May 21-23, 2007 |
|
| |
|
BIO International Convention
Boston Convention & Exhibition Center, Boston, MA; May 6-9, 2007 |
|
| |
|
Future Leaders in the Biotech Industry
Millennium Broadway Hotel, New York City, NY; March 29, 2007 |
|
| |
|
BioCEO & Investor Conference
The Waldorf Astoria Hotel, New York City, NY; February 12-14, 2007 |
|
| |
|
JP Morgan 25th Annual Health Care Conference
Westin St. Francis, San Francisco, CA; January 8-11, 2007 |
|
|
|
|
2008 NEWS |
| |
| METABOLEX COMPLETES PATIENT ENROLLMENT IN PHASE 2 TRIAL
OF MBX-8025 FOR TREATMENT OF DYSLIPIDEMIA
|
|
| June 16, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides. |
| |
|
More > |
| |
| METABOLEX APPOINTS DONALD HILL AS CHIEF FINANCIAL OFFICER |
|
| April 14, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions... |
| |
|
More > |
| |
| METABOLEX INITIATES PHASE 1 TRIAL OF MBX-2982 |
|
| March 26, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has dosed the first cohort of healthy subjects in a Phase 1 clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes ... |
| |
|
More > |
| |
|
|
|
